四環醫藥(00460.HK)：附屬旗下司美格魯(月太)注射液獲批開展臨床研究

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

四環醫藥(00460.HK)：附屬旗下司美格魯(月太)注射液獲批開展臨床研究

阿思達克 07-04 12:05

四環醫藥(00460.HK)宣布，旗下非全資附屬惠升生物研發的司美格魯(月太)注射液已獲國家藥品監督管理局批准開展臨床研究，用於治療2型糖尿病。此外，惠升生物研發的周圍神經病變藥物硫辛酸注射液近日獲得藥監局頒發的藥品註冊批件，視同通過仿製藥質量和療效一致性評價。(ca/w) ~

四環醫藥(00460.HK)

Relevant Stocks

四環醫藥(00460.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

四環醫藥(00460.HK)：附屬旗下司美格魯(月太)注射液獲批開展臨床研究

Services

About Us

Agreement Statement